Abstract
In this issue of Haematologica, Zinzani et al. describe their experience with the anti-CD30 antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin’s lymphoma. A total of 65 heavily pretreated patients who had been treated in a named patient program in nine Italian
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
